Tocilizumab (TCZ), also known as atlizumab, is a recombinant humanized anti-human interleukin 6 (IL-6) receptor monoclonal antibody of the immunoglobulin (Ig) IgG1 subclass with a H2L2 polypeptide structure. It is indicated in the following conditions reducing signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis (RA), for the treatment of giant cell arteritis (GCA) in adult patients, for the treatment of signs and symptoms of active polyarticular juvenile idiopathic arthritis (PJIA) in patients 2 years of age and older who have responded inadequately to previous therapy with disease-modifying antirheumatic drugs (DMARDs), for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with one or more non-steroidal anti-inflammatory drugs and systemic corticosteroids, for the treatment of patients with chimeric antigen receptor (CAR) T cell induced severe or life-threatening cytokine release syndrome (CRS), in accordance with patient populations specified for authorized CAR T cell products. Recently, the Food and Drug Administration (FDA) approved a phase III clinical trial of tocilizumab to treat hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19 pneumonia.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Tocilizumab, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.